Study of Serum Soluble Programmed Death Ligand 1 as a Prognostic Factor in Hepatocellular Carcinoma in Egyptian Patients
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
BACKGROUND: The expression of programmed cell death ligands on tumor cells has a role in the suppression of antitumor immunity, resulting in tumor immune evasion.
OBJECTIVE: In this study, we evaluated the prognostic value of the soluble form of programmed death-ligand1 (sPD-L1) in Egyptian hepatocellular carcinoma (HCC) patients.
METHODS: This prospective cohort study was performed between November 2016 to November 2018 on 85 individuals (25 HCC patients, 25 HCC with vascular invasion and/or extrahepatic metastasis, 25 patients with liver cirrhosis, 10 healthy controls). The levels of sPD-L1 were determined in all subjects and compared in different groups and stages of cirrhosis and HCC. The association between sPD-L1 levels and overall survival (OS) was assessed.
RESULTS: Significant statistical difference in sPD-L1 was detected between different study groups. The cut-off value for normal sPD-L1 was defined by high sPD-L1 levels determined in a healthy control cohort. It was 2.522 ng/ml. In HCC patients, cut-off value was 7.42 ng/ml (sensitivity 88%, specificity 100%). In HCC with vascular invasion or metastasis, cut-off value was 9.62 ng/ml (sensitivity 88%, specificity 88%). Patients with high serum sPD-L1 or serum bilirubin concentrations had an increased risk of mortality.
CONCLUSION: High sPD-L1 level could be a possible prognostic indicator for a poor outcome in liver cirrhosis and HCC patients. The predictive value of sPD-L1 levels for a successful anti- PD1/PD-L1 therapy should be investigated in the future.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Current cancer drug targets - 19(2019), 11 vom: 19., Seite 896-905 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
El-Gebaly, Fatma [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antitumor immunity |
|---|
| Anmerkungen: |
Date Completed 08.09.2020 Date Revised 08.09.2020 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1568009619666190718141647 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM301469156 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM301469156 | ||
| 003 | DE-627 | ||
| 005 | 20231225104703.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1568009619666190718141647 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1004.xml |
| 035 | |a (DE-627)NLM301469156 | ||
| 035 | |a (NLM)31538897 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a El-Gebaly, Fatma |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Study of Serum Soluble Programmed Death Ligand 1 as a Prognostic Factor in Hepatocellular Carcinoma in Egyptian Patients |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.09.2020 | ||
| 500 | |a Date Revised 08.09.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a BACKGROUND: The expression of programmed cell death ligands on tumor cells has a role in the suppression of antitumor immunity, resulting in tumor immune evasion | ||
| 520 | |a OBJECTIVE: In this study, we evaluated the prognostic value of the soluble form of programmed death-ligand1 (sPD-L1) in Egyptian hepatocellular carcinoma (HCC) patients | ||
| 520 | |a METHODS: This prospective cohort study was performed between November 2016 to November 2018 on 85 individuals (25 HCC patients, 25 HCC with vascular invasion and/or extrahepatic metastasis, 25 patients with liver cirrhosis, 10 healthy controls). The levels of sPD-L1 were determined in all subjects and compared in different groups and stages of cirrhosis and HCC. The association between sPD-L1 levels and overall survival (OS) was assessed | ||
| 520 | |a RESULTS: Significant statistical difference in sPD-L1 was detected between different study groups. The cut-off value for normal sPD-L1 was defined by high sPD-L1 levels determined in a healthy control cohort. It was 2.522 ng/ml. In HCC patients, cut-off value was 7.42 ng/ml (sensitivity 88%, specificity 100%). In HCC with vascular invasion or metastasis, cut-off value was 9.62 ng/ml (sensitivity 88%, specificity 88%). Patients with high serum sPD-L1 or serum bilirubin concentrations had an increased risk of mortality | ||
| 520 | |a CONCLUSION: High sPD-L1 level could be a possible prognostic indicator for a poor outcome in liver cirrhosis and HCC patients. The predictive value of sPD-L1 levels for a successful anti- PD1/PD-L1 therapy should be investigated in the future | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Programmed cell death ligand-1 | |
| 650 | 4 | |a antitumor immunity | |
| 650 | 4 | |a hepatocellular carcinoma | |
| 650 | 4 | |a metastasis | |
| 650 | 4 | |a prognosis | |
| 650 | 4 | |a tumor. | |
| 650 | 7 | |a B7-H1 Antigen |2 NLM | |
| 650 | 7 | |a Biomarkers, Tumor |2 NLM | |
| 650 | 7 | |a CD274 protein, human |2 NLM | |
| 700 | 1 | |a Abou-Saif, Sabry |e verfasserin |4 aut | |
| 700 | 1 | |a Elkadeem, Mahmoud |e verfasserin |4 aut | |
| 700 | 1 | |a Helmy, Amal |e verfasserin |4 aut | |
| 700 | 1 | |a Abd-Elsalam, Sherief |e verfasserin |4 aut | |
| 700 | 1 | |a Yousef, Mohamed |e verfasserin |4 aut | |
| 700 | 1 | |a Elkhouly, Reham Abdelkader |e verfasserin |4 aut | |
| 700 | 1 | |a Amer, Ibrahim Fathi |e verfasserin |4 aut | |
| 700 | 1 | |a El-Demerdash, Taher |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current cancer drug targets |d 2001 |g 19(2019), 11 vom: 19., Seite 896-905 |w (DE-627)NLM120490560 |x 1873-5576 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2019 |g number:11 |g day:19 |g pages:896-905 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1568009619666190718141647 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2019 |e 11 |b 19 |h 896-905 | ||